Marimed (MRMD) investor relations material

Executive summary

• Q1 2026 revenue reached $39.5 million, up 4.2% year-over-year, driven by expanded wholesale and retail distribution, with strong performances in Delaware and Maryland, partially offset by declines in Illinois and Massachusetts.

• Adjusted EBITDA rose to $3.6 million from $2.5 million, marking 25 consecutive quarters of positive Adjusted EBITDA and continued positive operating cash flow.

• Net loss attributable to common stockholders improved to $3.8 million from $5.5 million year-over-year, aided by a $0.7 million gain from Series B Convertible Preferred Stock restructuring.

• Retail revenue increased 5% year-over-year, driven by Delaware's adult use expansion, Maryland store growth, and a loyalty program accounting for 80% of retail sales.

• Strategic expansion continues with Delaware adult-use, licensing initiatives, and asset-light market entry.

Financial highlights

• Q1 2026 revenue: $39.5 million; GAAP gross margin: 38.7%; Non-GAAP gross margin: 40.1%.

• Gross profit was $15.8 million, with gross margin down 110 basis points year-over-year due to mix shifts.

• Operating expenses declined $500,000 year-over-year, mainly due to lower bad debt and marketing spend.

• Adjusted EBITDA margin expanded to 9.1% from 6.6% year-over-year.

• Cash and equivalents ended at $7.9 million, with positive operating cash flow and $800,000 in capital expenditures.

Outlook and guidance

• Management expects current cash and future funding to be sufficient for at least the next twelve months.

• Expansion planned in Ohio, Massachusetts, Delaware, and Pennsylvania, leveraging new dispensary cap increases and licensing opportunities.

• Focus remains on operational efficiency, branded product expansion, and asset-light growth strategies.

• Anticipates immediate tax benefits from medical cannabis rescheduling, with further clarity pending federal guidance.